Glaukos Corp GKOS
We take great care to ensure that the data presented and summarized in this overview for GLAUKOS Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GKOS
View all-
Black Rock Inc. New York, NY8.04MShares$758 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.97MShares$563 Million0.02% of portfolio
-
State Street Corp Boston, MA2.06MShares$194 Million0.01% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN1.93MShares$182 Million0.08% of portfolio
-
Invesco Ltd. Atlanta, GA1.46MShares$137 Million0.04% of portfolio
-
Brown Capital Management LLC Baltimore, MD1.35MShares$127 Million4.79% of portfolio
-
Lord, Abbett & Co. LLC Jersey City, NJ1.31MShares$123 Million0.62% of portfolio
-
Primecap Management CO Pasadena, CA1.21MShares$114 Million0.14% of portfolio
-
Geode Capital Management, LLC Boston, MA1.2MShares$113 Million0.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.19MShares$112 Million0.03% of portfolio
Latest Institutional Activity in GKOS
Top Purchases
Top Sells
About GKOS
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Insider Transactions at GKOS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 21
2025
|
Alex R. Thurman SVP & CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
2,484
-4.68%
|
$240,948
$97.09 P/Share
|
|
Apr 21
2025
|
Thomas William Burns CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,957
-5.18%
|
$771,829
$97.09 P/Share
|
|
Apr 01
2025
|
Alex R. Thurman SVP & CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
311
-0.58%
|
$30,167
$97.09 P/Share
|
|
Apr 01
2025
|
Thomas William Burns CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,059
-2.58%
|
$393,723
$97.09 P/Share
|
|
Apr 01
2025
|
Joseph E Gilliam PRESIDENT & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,922
-1.72%
|
$186,434
$97.09 P/Share
|
|
Apr 01
2025
|
Tomas Navratil CHIEF DEVELOPMENT OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
484
-0.59%
|
$46,948
$97.09 P/Share
|
|
Mar 31
2025
|
Thomas William Burns CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,098
-0.69%
|
$107,604
$98.42 P/Share
|
|
Mar 31
2025
|
Tomas Navratil CHIEF DEVELOPMENT OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
510
-0.62%
|
$49,980
$98.42 P/Share
|
|
Mar 25
2025
|
Tomas Navratil CHIEF DEVELOPMENT OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
6,942
-3.94%
|
$708,084
$102.11 P/Share
|
|
Mar 25
2025
|
Joseph E Gilliam PRESIDENT & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,320
-6.51%
|
$1,664,640
$102.11 P/Share
|
|
Mar 25
2025
|
Thomas William Burns CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,439
-2.83%
|
$962,778
$102.11 P/Share
|
|
Mar 25
2025
|
Alex R. Thurman SVP & CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,520
-0.93%
|
$162,640
$107.38 P/Share
|
|
Mar 25
2025
|
Alex R. Thurman SVP & CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
4,844
-4.13%
|
$494,088
$102.11 P/Share
|
|
Mar 17
2025
|
Joseph E Gilliam PRESIDENT & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,028
-0.8%
|
$104,856
$102.19 P/Share
|
|
Mar 17
2025
|
Tomas Navratil CHIEF DEVELOPMENT OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
958
-1.06%
|
$97,716
$102.19 P/Share
|
|
Mar 17
2025
|
Alex R. Thurman SVP & CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
489
-0.81%
|
$49,878
$102.19 P/Share
|
|
Mar 17
2025
|
Thomas William Burns CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,013
-1.18%
|
$205,326
$102.19 P/Share
|
|
Mar 13
2025
|
Joseph E Gilliam PRESIDENT & COO |
BUY
Grant, award, or other acquisition
|
Direct |
27,833
+6.96%
|
-
|
|
Mar 13
2025
|
Tomas Navratil CHIEF DEVELOPMENT OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
18,061
+6.38%
|
-
|
|
Mar 13
2025
|
Alex R. Thurman SVP & CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
8,313
+6.66%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 169K shares |
|---|---|
| Exercise of conversion of derivative security | 117K shares |
| Open market or private sale | 104K shares |
|---|---|
| Payment of exercise price or tax liability | 74.7K shares |